Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - talidomidas - daugybinė mieloma - imunosupresantai - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidinas - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antinavikiniai vaistai - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hidrochloridas - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresantai - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - kiti antianemic preparatai - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antinavikiniai vaistai - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidinas - leukemija, mieloidas, ūmus - antinavikiniai vaistai - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bela-pharm gmbh & co. kg (vokietija) - injekcinis tirpalas - prednisolon tabletta prednisolon tabletta 1 ml yra: oksitocino - 16,6 mcg. - kumelėms, karvėms, avims, ožkoms, kiaulėms, kalėms ir katėms gimdos susitraukimams skatinti vaikavimosi metu ir tuoj po atsivedimo.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sia pharmidea - karbetocinas - injekcinis tirpalas - 100 µg/ml - carbetocin

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

biowet -puławy sp. z o.o (lenkija) - injekcinis tirpalas - 1 ml tirpalo yra: oksitocino - 10 tv. - karvėms, kumelėms, kiaulėms, avims, kalėms ir katėms gimdos raumenų susitraukimui atsivedimo metu ir po atsivedimo, norint užkirsti kelią kraujavimui ir placentos užsilaikymui, taip pat gimdos involiucijos po atsivedimo procesui skatinti, taip pat pieno išskyrimui sukelti, esant agalaktijai po atsivedimo.